## WHAT IS CLAIMED IS:

1

TŲ

M

口 [1]10

<u>=</u> 12

13

14

15

16

17

1

1

2

3

1

1

1

1

A compound of formula (1):

wherein

each of  $R_1$ ,  $R_2$ ,  $R_4$ ,  $R_4$ ,  $R_7$ ,  $R_{11}$ ,  $R_{12}$ ,  $R_{15}$ ,  $R_{16}$ ,  $R_{17}$ , and  $R_{17}$ , independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid;

 $R_3$  is X-Y-, wherein X is hydrogen, amind, carboxyl, halo, sulfonic acid, -O-sulfonic acid, or alkyl; Y is -S-, -NH-, -N(alkyl)-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -CO- NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-;  $R_5$  and  $R_6$ , together, are -O-; or  $R_5$  and  $R_6$ , together, are a double bond between C-5 and C-6, and  $R_7$  is oxo;

each of  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{13}$ , and  $R_{14}$ , independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino; and n is 0, 1, or 2.

- 2. The compound of claim 1, wherein X is hydrogen or amino, and Y is -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-.
- $\chi$  3. The compound of claim 1, wherein  $R_5$  and  $R_6$ , together, are -O-.

1

1

1

- The compound of claim 3, wherein X is hydrogen or amino, and Y is -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-.
  - 15. The compound of claim 4, wherein X is hydrogen, and Y is -SO<sub>3</sub>.
  - 6. The compound of claim 3, wherein -O- is on the  $\alpha$  side of C-5 and C-6.
  - 7. The compound of claim 6, wherein X is hydrogen or amino, and Y is -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-.
    - \*8. The compound of claim 7, wherein X is hydrogen, and Y is -SO<sub>3</sub>.
    - 9. The compound of claim 8, wherein  $R_1$ ,  $R_2$ ,  $R_4$ ,  $R_4$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{11}$ ,  $R_{12}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$ , and  $R_{17}$  are hydrogen; and each of  $R_{10}$ ,  $R_{13}$ , and  $R_{17}$ , independently, is alkyl.
    - 10. The compound of claim 9, wherein the compound is  $5\alpha$ ,  $6\alpha$ -epoxycholesterol-3-sulfate.
- 1 11. An antibody which is specifically against the compound of claim 10.
  - 12. The compound of claim 1, wherein R<sub>5</sub> and R<sub>6</sub>, together, are a double bond between C-5 and C-6, and R<sub>7</sub> is oxo.
- 1 13. The compound of claim 12, wherein X is hydrogen or amino, and Y is -O-SO<sub>2</sub>-,
  2 -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or
  3 -N(alkyl)-CO-.
  - 14. The compound of claim 13, wherein X is hydrogen, and Y is -SO<sub>3</sub>-O-.

5

7

8

9

10

11

12

13

14

15

16

15. The compound

- 15. The compound of claim 14, wherein  $R_1$ ,  $R_2$ ,  $R_4$ ,  $R_4$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{11}$ ,  $R_{12}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$ , and  $R_{17}$  are hydrogen; and each of  $R_{10}$ ,  $R_{13}$ , and  $R_{17}$ , independently, is alkyl.
- 1

. 1

2

- 16. The compound of claim 15, wherein the compound is 7-keto-cholesterol-3-sulfate.
- 1
- $\times$ 17. An antibody which is specifically against the compound of claim 16.
- 1

1

2

18. A method of treating hypocholesterolemia, comprising administering to a subject in need thereof an effective amount of a compound of formula (1):

wherein

each of R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub>, R<sub>4</sub>, R<sub>7</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>15</sub>, R<sub>16</sub>, R<sub>17</sub>, and R<sub>17</sub>, independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl that is optionally inserted with -O-, -S-, -NH-, -N(alkyl)-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid;

 $R_3$  is X-Y-, wherein X is hydrogen, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, or alkyl; Y is -S-, -NH-, -N(alkyl)-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-;  $R_5$  and  $R_6$ , together, are -O-; or  $R_5$  and  $R_6$ , together, are a double bond between C-5 and C-6, and  $R_7$  is oxo;

each of  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{13}$ , and  $R_{14}$ , independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino; and n is 0, 1, or 2.

1

-N(alkyl)-CO-.

1

19. The method of claim 18, wherein X is hydrogen or amino, and Y is -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or 2 -N(alkyl)-CO-. 3 1  $\downarrow$  20. The method of claim 18, wherein R<sub>5</sub> and R<sub>6</sub>, together, are -O-. 1 1 21. The method of claim 20, wherein X is hydrogen or amino, and Y is -O-SO<sub>2</sub>-, . 1 -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or 2 -N(alkyl)-CO-. 3 1 22. The method of claim 21, wherein X is hydrogen, and Y is -SO<sub>3</sub>-O-. 1  $\swarrow$  23. The method of claim 20, wherein -O- is on the  $\alpha$  side of C-5 and C-6. 24. The method of claim 23, wherein X is hydrogen or amino, and Y is -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or 3 1 1 1 1 -N(alkyl)-CO. 25. The method of claim 24, wherein X is hydrogen, and Y is -SO<sub>3</sub>-O-.  $\angle$  26. The method of claim 25, wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub>, R<sub>4</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>14</sub>, R<sub>15</sub>, R<sub>16</sub>, 1 and  $R_{17}$  are hydrogen, and each of  $R_{10}$ ,  $R_{13}$ , and  $R_{17}$ , independently, is alkyl. 2 1  $\sim$  27. The method of claim 26, wherein the compound is  $5\alpha$ ,  $6\alpha$ -epoxycholesterol-3-sulfate. 1 1  $\angle$  28. The method of claim 18, wherein R<sub>5</sub> and R<sub>6</sub>, together, are a double bond between C-5 1 and C-6, and  $R_7$  is oxo. 2 1 ∠ 29. The method of claim 28, wherein X is hydrogen or amino, and Y is -O-SO<sub>2</sub>-, 1 -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or 2

- 1 1
- 1
- 2 1
- 1

- - - 8
    - 9
    - 10
  - 11
  - 12 13
  - 14
  - 15
  - 16 17
    - 1

- 30. The method of claim 29, wherein X is hydrogen, and Y is -SO<sub>3</sub>-O-.
- 31. The method of claim 30, wherein  $R_1$ ,  $R_2$ ,  $R_4$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{11}$ ,  $R_{12}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$ , and R<sub>17</sub> are hydrogen, and each of R<sub>10</sub>, R<sub>13</sub>, and R<sub>17</sub>, independently, is alkyl.
- 32. The method of claim 31, wherein the compound is 7-keto-cholesterol-3-sulfate.
  - 33. A pharmaceutical composition comprising a compound of formula (1):

wherein

each of  $R_1$ ,  $R_2$ ,  $R_4$ ,  $R_4$ ,  $R_7$ ,  $R_{11}$ ,  $R_{12}$ ,  $R_{15}$ ,  $R_{16}$ ,  $R_{17}$ , and  $R_{17}$ , independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl that is optionally inserted with -Q-, -S-, -NH-, -N(alkyl)-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid;

R<sub>3</sub> is X-Y-, wherein X is hydrogen, amino, carbox 1, halo, sulfonic acid, -O-sulfonic acid, or alkyl; Y is -S-, -NH-, -N(alkyl)-, -SO-, -SO<sub>2</sub>-, -SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-;  $R_5$  and  $R_6$ , together, are -O-; or  $R_5$  and  $R_6$ , together, are a double bond between C-5 and C-6, and  $R_7$  is oxo;

- each of R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>13</sub>, and R<sub>14</sub>, independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino; and n is 0, 1, or 2;
- and a pharmaceutically acceptable carrier.

1

1

1

1

1

1

- 1 34. The composition of claim 33, wherein X is hydrogen or amino, and Y is -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or 2 -N(alkyl)-CO-. 3
  - 35. The composition of claim 33, wherein  $R_5$  and  $R_6$ , together, are -O-.
- 236. The composition of claim 35, wherein X is hydrogen or amino, and Y is -O-SO<sub>2</sub>-, 1 2 -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or 3 -N(alkyl)-CO-.
  - ∠37. The composition of claim 36, wherein X is hydrogen, and Y is -SO<sub>3</sub>-O-.
  - $\angle$  38. The composition of claim 35, wherein -O- is on the  $\alpha$  side of C-5 and C-6.
  - 39. The composition of claim 38, wherein X is hydrogen or amino, and Y is -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-.40. The composition of claim 39, wherein X is hydrogen, and Y is -SO<sub>3</sub>-O-.
  - $\angle$  41. The composition of claim 40, wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>14</sub>, R<sub>15</sub>,  $R_{16}$ , and  $R_{17}$  are hydrogen, and each of  $R_{10}$ ,  $R_{13}$ , and  $R_{17}$ , independently, is alkyl.
- 42. The composition of claim 41, wherein the compound is  $5\alpha$ ,  $6\alpha$ -epoxycholesterol-3-1 2 sulfate.
- 43. The composition of claim 33, wherein R<sub>5</sub> and R<sub>6</sub>, together, are a double bond between 1 C-5 and C-6, and  $R_7$  is oxo. 2
- 1 44. The composition of claim 33, wherein X is hydrogen or amino, and Y is -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or 2 -N(alkyl)-CO-. 3

1

1

1

2

- 45. The composition of claim 44, wherein X is hydrogen, and Y is -SO<sub>3</sub>-O-.
- 46. The composition of claim 45, wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub>, R<sub>4</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>14</sub>, R<sub>15</sub>,
   R<sub>16</sub>, and R<sub>17</sub> are hydrogen, and each of R<sub>10</sub>, R<sub>13</sub>, and R<sub>17</sub>, independently, is alkyl.
  - 47. The composition of claim 46, wherein the compound is 7-keto-cholesterol-3-sulfate.
  - 48. A method of evaluating a compound for its agonistic effect on an liver X receptor, comprising:

contacting the compound to be evaluated with the liver X receptor in the presence of a compound of formula (1):


wherein

7 each of  $R_1$ ,  $R_2$ ,  $R_4$ ,  $R_4$ ,  $R_7$ ,  $R_{11}$ ,  $R_{12}$ ,  $R_{15}$ ,  $R_{16}$ ,  $R_{17}$ , and  $R_{17}$ , independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic acid, or 8 alkyl that is optionally inserted with -O-, -S-, -NH-, -N(alkyl)-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, 9 -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or 10 -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, 11 12 carboxyl, sulfonic acid, or -O-sulfonic acid; R<sub>3</sub> is X-Y-, wherein X is hydrogen, amino, carboxyl, halo, sulfonic acid, -O-sulfonic 13 acid, or alkyl; Y is -S-, -NH-, -N(alkyl)-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, 14 -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-; 15 R<sub>5</sub> and R<sub>6</sub>, together, are -O-; or R<sub>5</sub> and R<sub>6</sub>, together, are a double bond between C-5 16 and C-6, and  $R_7$  is oxo; 17

2

1

2



55. The method of claim 54, wherein X is hydrogen, and Y is  $-SO_3-O-$ . 1

-N(alkyl)-CO-.

56. The method of claim 55, wherein  $R_1$ ,  $R_2$ ,  $R_4$ ,  $R_4$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{11}$ ,  $R_{12}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$ , and  $R_{17}$  are hydrogen, and each of  $R_{10}$ ,  $R_{13}$ , and  $R_{17}$ , independently, is alkyl.

 $\swarrow$  57. The method of claim 56, wherein the compound is  $5\alpha$ ,  $6\alpha$ -epoxycholesterol-3-sulfate. 1

- 58. The method of claim 48, wherein R<sub>5</sub> and R<sub>6</sub>, together, are a double bond between C-5 and C-6, and R<sub>7</sub> is oxo.
- 1 \( \sum 59\). The method of claim 48, wherein X is hydrogen or amino, and Y is -O-SO<sub>2</sub>-,
  2 -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or
  3 -N(alkyl)-CO-.
- 1 60. The method of claim 59, wherein X is hydrogen, and Y is -SO<sub>3</sub>-O-.
- - 62. The method of claim 61, wherein the compound is 7-keto-cholesterol-3-sulfate.